EVALUATION OF CEFTAZIDIME: ITS CLINICAL EFFECTS ON SURGICAL INFECTIONS AND ITS CONCENTRATION IN BILE AND PANCREATIC JUICE

• Published in: CHEMOTHERAPY Vol. 31; no. Supplement3; pp. 703 - 709
• Main Authors: YAMADA, YOSHINORI, IKEHATA, YUKIHIKO, MATSUDA, KOHICHI, IWAMOTO, MINORU, FUKAMI, HIROYA, SUMIYAMA, MASAO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1983
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.31.Supplement3_703

Clinical effects of Ceftazidime (CAZ, SN401) were studied in surgical infections as well as for its penetration into bile and pancreatic juice. Ceftazidime was administered intravenously to 15 patients with various surgical infections including acute panperitonitis, acute appendicitis, subphrenic abscess, postoperative wound infection, etc. The daily dose of CAZ was 1.5 to 3 g in 14 adults and 500 mg in one 3-year-old child. Favourable clinical effects were obtained in 12 patients (80%). Surgical treatments were also performed in all these patients except for 1 with urinary tract infections after Miles' abdominoperineal resection. Clinical effects in three patients with subphrenic abscess were all assessed to be fair or poor. Bacteriologically, the organisms isolated from these 3 cases consisted of 2 different species. Neither adverse effect nor abnormal laboratory finding related to the drug was observed during the study period. Concentrations of CAZ in bile were determined in 2 patients who had undergone cholecystectomy and choledochotomy. During the first 4 hours after intravenous injection of 1 g of CAZ, the bile levels were 10μg/ml or higher, with the maximum levels of 29.4 and 24.5μg/ml, respectively. In the pancreatic juice samples collected hourly from a patient with postoperative pancreatic cyst, the peak level of 6.22μg/ml was attained in the samples collected between 2 and 4 hours after the injection. Through this study, CAZ was thought to be useful in surgical field, especially in postoperative infections.